Allopurinol and the risk of stroke in older adults receiving medicare

BMC Neurology

Table 4 Association of risk factors with incident stroke^a in patients who received allopurinol

	Univariate		Multivariable-adjusted (model 1)*		Multivariable-adjusted (model 2)**
	HR (95 % CI)	P-value	HR (95 % CI)	P-value	HR (95 % CI)	P-value
Age
65- <75	Ref		Ref		Ref
75- <85	1.63 (1.48, 1.79)	<0.0001	1.54 (1.40, 1.70)	<0.0001	1.54 (1.40, 1.70)	<0.0001
≥ 85	2.09 (1.86, 2.35)	<0.0001	1.91 (1.69, 2.15)	<0.0001	1.91 (1.69, 2.16)	<0.0001
Gender
Male	Ref		Ref		Ref
Female	1.21 (1.12, 1.32)	<0.0001	1.09 (1.00, 1.19)	0.05	1.09 (1.00, 1.19)	0.05
Race
White	Ref		Ref		Ref
Black	1.40 (1.24, 1.57)	<0.0001	1.37 (1.21, 1.54)	<0.0001	1.36 (1.21, 1.53)	<0.0001
Other	1.09 (0.94, 1.26)	0.27	1.09 (0.94, 1.27)	0.23	1.09 (0.94, 1.26)	0.26
Charlson- Romano score	1.11 (1.10, 1.12)	<0.0001	1.10 (1.09, 1.11)	<0.0001	1.10 (1.09, 1.11)	<0.0001
Cardiovascular drug use (Ref, no use)
Statins	0.93 (0.75, 1.15)	0.49	0.91 (0.73, 1.13)	0.39	0.91 (0.73, 1.13)	0.38
Beta blockers	1.38 (1.15, 1.67)	0.0007	1.40 (1.15, 1.70)	0.0008	1.40 (1.15, 1.70)	0.0008
Diuretics	1.05 (0.86, 1.27)	0.63	0.97 (0.79, 1.18)	0.74	0.96 (0.79, 1.18)	0.72
ACE inhibitor	0.92 (0.73, 1.18)	0.52	0.97 (0.76, 1.24)	0.78	0.97 (0.76, 1.23)	0.78
Allopurinol use (Ref, none)	0.92 (0.84, 1.01)	0.07	0.91 (0.83, 0.99)	0.04	-	-
Allopurinol use duration
None	Ref				Ref
1 - 180 days	1.02 (0.89, 1.15)	0.81			1.00 (0.88, 1.14)	0.97
181 days - 2 years	0.90 (0.80, 1.01)	0.07			0.88 (0.78, 0.99)	0.03
> 2 years	0.78 (0.64, 0.96)	0.02			0.79 (0.65, 0.96)	0.02

* Model 1 = Allopurinol use + age + race + gender + Charlson score + beta blockers + diuretics + ACE inhibitors + Statins
** Model 2 = Allopurinol use duration + age + race + gender + Charlson score + beta blockers + diuretics + ACE inhibitors + Statins
^aNo stroke within the baseline period of 365 days before the index date of allopurinol episode

ISSN: 1471-2377